Senti Biosciences Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $55KTTM through 30 Jun 2026
Net Income -$49.6MTTM through 30 Jun 2026
Free Cash Flow -$44.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| Operating Margin | -99,434.5% |
| Net Margin | -90,116.4% |
Returns
-134.8%ROA
Balance Sheet Health
Debt / Equity7.46x
Current Ratio0.83x
Net Debt$10.2M
Cash & Equivalents$6.5M
Quality Metrics
Altman Z-Score-21.27
Piotroski F-Score1 / 9
FCF Margin-81,069.1%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $22K
Diluted EPS-$1.69TTMFY2025: $-2.73
Dividend
No dividend
Capital Allocation
Capex Intensity11,885.5%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.